Status:
NOT_YET_RECRUITING
Role of MDSCs and Cancer Stem Cells and Their Cross Talks in NSCLC
Lead Sponsor:
University Hospital, Bordeaux
Conditions:
Lung Neoplasms
Myeloid-Derived Suppressor Cells
Eligibility:
All Genders
18+ years
Brief Summary
Immunotherapy have revolutionized the field of oncology, but response rates are low and all patients relapse, due to cellular and soluble immunosuppressive mechanisms. MDSC are one of the most importa...
Detailed Description
In recent years, immune-based therapies have revolutionized the field of oncology by significantly improving survival of cancer patients. Despite sustained responses, only 20% to 40% of cancer patient...
Eligibility Criteria
Inclusion
- consecutive patients
- lung carcinoma surgically treated by surgery only
Exclusion
- patient receiving chemotherapy, radiotherapy or immunotherapy in the neoadjuvant setting (all objectives)
- patient with concomitant or previous cancer (in the 2 years)
Key Trial Info
Start Date :
December 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06024226
Start Date
December 1 2025
End Date
December 1 2027
Last Update
July 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Bordeaux - Hôpital Saint-André, Service d'Oncologie Médicale
Bordeaux, France, 33000